Beijing Tiantan Biological Products (600161) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 increased 7.84% year-over-year to RMB 1.32 billion, driven by higher sales volume.

• Net profit attributable to shareholders declined 22.90% to RMB 244 million, as product price decreases outweighed volume gains.

• Management plans to strengthen production-sales coordination and cost control to enhance profitability.

• Cash flow from operating activities dropped sharply to -RMB 302 million from RMB 469 million in Q1 2024.

Financial highlights

• Operating income reached RMB 1.32 billion, up 7.84% year-over-year.

• Net profit attributable to shareholders was RMB 244 million, down 22.90% year-over-year.

• Basic and diluted EPS: RMB 0.12, down from RMB 0.16 in Q1 2024.

• Operating cash flow: -RMB 302 million, a significant decline from positive RMB 469 million a year ago.

• Total assets at quarter-end: RMB 16.24 billion, up 2.31% from year-end 2024.

Outlook and guidance

• Cash flow was negatively impacted by a new sales credit policy and increased tax payments.

• Management expects continued quarterly fluctuations due to market environment and sales strategies, with a focus on cost control and improving sustainable profitability.